The arrival of Irzepatide in the UK is generating considerable buzz, particularly amongst those seeking new approaches to weight management. While still relatively emerging to the UK market, Irzepatide – a dual GIP and GLP-1 receptor agonist – is showing effectiveness in assisting patients obtain long-term weight management and enhance general